European urology oncology · 2025
Higher Preoperative Maximum Standardised Uptake Values Are Associated with a Higher Risk of Metastases After Robot-assisted Radical Prostatectomy for Patients Undergoing 68Ga-PSMA-11 and 18F-DCFPyL Positron Emission Tomography/Computed Tomography.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
de Bie K C C, Creanza M F, Bodar Y J L, Donswijk M L, van Leeuwen P J, van Moorselaar R J A, Oprea-Lager D E, Vis A N
Аннотация
BACKGROUND AND OBJECTIVE: Prostate-specific membrane antigen (PSMA) expression on positron emission tomography/computed tomography (PET/CT), semiquantitatively expressed as the standardised uptake value (SUVmax), is increasingly recognised as a prognostic factor and may predict metastatic progression after treatment. This study aims to evaluate the predictive value of SUVmax on preoperative PSMA PET/CT for metastatic development after robot-assisted radical prostatectomy (RARP).
METHODS: This retrospective two-centre study included patients with nonmetastatic primary prostate cancer who underwent [68Ga]Ga-PSMA-11 or [18F]DCFPyL PSMA PET/CT prior to RARP. The minimum follow-up period was 1 yr. Metastases were assessed by restaging PSMA PET/CT at biochemical recurrence. SUVmax was calculated for the dominant intraprostatic lesion on preoperative PSMA PET/CT. Multivariable Cox regression included SUVmax, clinical tumour stage (cT), initial prostate-specific antigen density, percentage positive biopsy cores, and biopsy International Society of Urological Pathology grade group. SUVmax thresholds and model performance were investigated.
KEY FINDINGS AND LIMITATIONS: A total of 293 patients underwent preoperative PSMA PET/CT, of whom 53 developed metastases after a median follow-up of 39 mo (interquartile range [IQR] 29-54). SUVmax was higher in participants who developed metastases at 2-yr follow-up than in those without metastases (median 8.8; IQR 7.1-16 vs 7.8; IQR 5.7-13; p = 0.015). An SUVmax of >10 was associated with an increased metastatic risk (hazard ratio [HR] 1.81; 95% confidence interval [CI] 1.04-3.13; p = 0.035) and log-SUVmax independently predicted metastases (HR 2.80; 95% CI 1.02-7.70; p = 0.046). The limitations include potential selection and detection biases due to selective follow-up imaging and nonstandardised treatment decisions.
CONCLUSIONS AND CLINICAL IMPLICATIONS: In patients with primary prostate cancer, preoperative SUVmax is associated with metastatic progression after RARP. An SUVmax of >10 may aid in risk stratification for adverse outcomes.
METHODS: This retrospective two-centre study included patients with nonmetastatic primary prostate cancer who underwent [68Ga]Ga-PSMA-11 or [18F]DCFPyL PSMA PET/CT prior to RARP. The minimum follow-up period was 1 yr. Metastases were assessed by restaging PSMA PET/CT at biochemical recurrence. SUVmax was calculated for the dominant intraprostatic lesion on preoperative PSMA PET/CT. Multivariable Cox regression included SUVmax, clinical tumour stage (cT), initial prostate-specific antigen density, percentage positive biopsy cores, and biopsy International Society of Urological Pathology grade group. SUVmax thresholds and model performance were investigated.
KEY FINDINGS AND LIMITATIONS: A total of 293 patients underwent preoperative PSMA PET/CT, of whom 53 developed metastases after a median follow-up of 39 mo (interquartile range [IQR] 29-54). SUVmax was higher in participants who developed metastases at 2-yr follow-up than in those without metastases (median 8.8; IQR 7.1-16 vs 7.8; IQR 5.7-13; p = 0.015). An SUVmax of >10 was associated with an increased metastatic risk (hazard ratio [HR] 1.81; 95% confidence interval [CI] 1.04-3.13; p = 0.035) and log-SUVmax independently predicted metastases (HR 2.80; 95% CI 1.02-7.70; p = 0.046). The limitations include potential selection and detection biases due to selective follow-up imaging and nonstandardised treatment decisions.
CONCLUSIONS AND CLINICAL IMPLICATIONS: In patients with primary prostate cancer, preoperative SUVmax is associated with metastatic progression after RARP. An SUVmax of >10 may aid in risk stratification for adverse outcomes.